VYGR
Voyager Therapeutics, Inc.
$4.05
+2.27%
2026-05-08
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Key Fundamentals
Forward P/E
-2.31
EPS (TTM)
$-2.04
ROE
-48.3%
Revenue Growth (YoY)
144.3%
Profit Margin
-296.5%
Debt/Equity
18.61
Price/Book
1.20
Beta
1.26
Market Cap
$240.8M
Avg Volume (10D)
431K
Recent Breakout Signals
No recent breakout signals detected for VYGR.
Recent Price Range (60 Days)
60D High
$5.48
60D Low
$3.26
Avg Volume
663K
Latest Close
$4.05
Get breakout alerts for VYGR
Sign up for Breakout Scanner to receive daily notifications when VYGR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Voyager Therapeutics, Inc. (VYGR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors VYGR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. VYGR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.